• <pre id="bq1g9"><label id="bq1g9"></label></pre><pre id="bq1g9"></pre>
  • <td id="bq1g9"></td>
      <acronym id="bq1g9"></acronym>

        <td id="bq1g9"><ruby id="bq1g9"></ruby></td>

        <track id="bq1g9"><strike id="bq1g9"></strike></track>

        <tr id="bq1g9"><s id="bq1g9"></s></tr>

        <td id="bq1g9"><option id="bq1g9"></option></td>
      1. <p id="bq1g9"><ruby id="bq1g9"><menu id="bq1g9"></menu></ruby></p>
          <track id="bq1g9"><ruby id="bq1g9"><tt id="bq1g9"></tt></ruby></track>
          Centennial HEC
          Centennial HEC

          Biomedicine Industry

          The biomedical industry mainly includes Sunshine Lake Pharma Co., Ltd. and HEC Pharm Co., Ltd. two business systems. Sunshine Lake Pharma Co., Ltd. includes HEC Pharmaceutical Research Institute, domestic preparation business ("HEC Changjiang Pharmaceutical", which has been listed in Hong Kong stock market) and pharmaceutical business for foreign markets; HEC Pharm Co., Ltd. is mainly engaged in bio-fermentation API.

          Pharmaceutical Research Institute

          HEC Research Institute

          Research Institute
          The Pharmaceutical Research Institute was established in 2005, driven by the twin engines of "innovation" and "internationalization" to develop and commercialize small molecule innovative drugs, biological innovative drugs and similar drugs, first generic drugs and innovative preparations around the world, involving infectious diseases such as hepatitis B and C, tumor diseases such as esophageal cancer, endocrine and metabolic diseases such as diabetes and other fields; the cumulative investment in research and development exceeds 20 billion yuan.
          Research Scale
          • 1 National key laboratory
            1 National key laboratory
            A national key laboratory for the R&D of new anti-infective drugs is approved to establish, undertaking and participating in the R&D of 25 major national projects.
          • 3 Platforms
            3 Platforms
            Small molecule R&D platform, macromolecule R&D platform, generic drug and innovative formulation platform, with complete independent R&D capability
          • 100+ Research projects
            100+ Research projects
            43 Class 1 new drugs (33 chemical innovative drugs, 10 biological innovative drugs), 8 biosimilar drugs, 50+ generic drugs & improved new drug projects
          • 50 Class 1 new drug products
            50 Class 1 new drug products
            28 Products are in the clinical stage, 6 are in the clinical phase III, 4 have completed the overseas clinical phase I, and 1 has FDA orphan drug qualification.
          • 1500+ Researchers
            1500+ Researchers
            There are 1500+ R&D personnel, and the proportion of masters and doctors is more than 60%.
          • 2000+ Patents
            2000+ Patents
            There are 2000+ patents in the biomedical sector, in which 800+ are overseas patents.
          • 6-Fold GMP certification
            6-Fold GMP certification
            Possess 6-fold GMP certification from the United States, the European Union, China, WHO, Australia, and Belarus, forming an international standard pharmaceutical production system
          • 15+ Countries and Regions
            15+ Countries and Regions
            Serve customers covering five continents, accumulatively enter 15+ countries and regions, create a global sales network layout
          • Advantages of the research institute
            Advantages of the research institute
            It is equipped with advanced R&D software, hardware and environment, 50,000 square meters of laboratories, completely independent R&D capabilities, and a complete R&D system, which can quickly realize industrialization; it conducts R&D cooperation with international top pharmaceutical companies. It has the ability to develop generic drugs and innovative preparations and clinical trials that meet European and American standards.
          • Strength of the research institute
            Strength of the research institute
            It has abundant product clusters, and the R&D strength ranks first in the domestic echelon. It focuses on infection, tumor, chronic disease (metabolism) and other market fields. There are 100 products on the market, including 1 Class 1 new drug. 50 Class 1 new drugs are under development, 11 of which are in clinical phase II/III. Research institute has entered the forefront of China's new drug R&D pipeline and innovative chemical drugs.
          The echelon of innovative drug pipeline is clearly stratified and competitive
          Therapeutic field Medicine name Indication Clinical phase Ⅰ Clinical phase Ⅱ Clinical phase Ⅲ Come into the market
          Infection field
          Emitasvir Hepatitis C
          Antaitasvir Hepatitis C
          Yiqibuvir Hepatitis C
          Morphothiadine Hepatitis B
          Forethiadine Hepatitis B
          HEC116094 Influenza
          Tumor/ Immune field
          Larotinib Esophageal Cancer
          Clifutinib AML
          HEC169096 Solid Tumor
          HEC81885 Solid Tumor
          Metabolic/chronic disease
          Rongliflozin Diabetes
          Yinfenidone IPF/PF-ILD
          HEC96719 NASH
          HEC93077 Gout
          HEC73077 Diabetic nephropathy
          HEC95468 Pulmonary hypertension
          HEC53856 Renal anemia
          HEC126764 Diabetic nephropathy
          Neuropsychiatric field
          Mitizodone Depression
          HEC137076 Migraine
          Note: Products in the early stages of development are not listed in the product pipeline above    Conduct overseas clinical trials    Foreign cooperation

          Domestic preparation business [HEC Changjiang Pharmaceutical (01558.HK)]

          HEC Pharmaceutical (01558.HK) is listed on the main board of Hong Kong. Its main products include anti-influenza drug Kewei (oseltamivir phosphate capsules and granules), insulin series products, emitavir phosphate cap

          Kewei
          Kewei is the recommended drug for the prevention and treatment of influenza in the world, and it is also a safer and more effective drug for the treatment of influenza in children at this stage; HEC holds a patent for the professional Kewei granule process that is more suitable for children.

          Insulin

          There are 120 million people with diabetes in China, and the market space for new and alternative markets is vast. HEC drug recombinant human insulin injection and insulin glargine injection have been approved for marketing, and won the bid for national centralized procurement. Insulin Aspart Injection and Insulin Aspart 30 Injection have been approved for marketing in China in 2022, and a series of diabetes products such as liraglutide will be launched in the future; the clinical development of insulin glargine and insulin aspart in the United States is progressing smoothly, and it is expected that it will be approved for listing in the United States in 2023 and 2024, respectively, entering the US$15 billion insulin market.

           

          Emitasvir Phosphate Capsules

          Emitasvir phosphate, launched in December 2020, is China's first fully self-developed oral small molecule anti-hepatitis C drug. Emitasvir phosphate has a cure rate of 99.8% in the treatment of Chinese hepatitis C genotype 1 patients. It has won the National Twelfth Five-Year Plan and the Thirteenth Five-Year Plan for Major New Drug Creation Projects. It has entered the National Medical Insurance Catalogue in December 2021, and is currently in rapid volume.

           

          Centralized procurement products

          HEC pharmaceutial have been approved for 38 domestic consistency evaluation drugs, and 17 varieties of centralized procurement have been won the bid, and the varieties of centralized procurement have become the rapid growth point of HEC drugs. 

          圖片名稱
          圖片名稱
          圖片名稱
          圖片名稱
          圖片名稱
          圖片名稱
          圖片名稱
          圖片名稱

          Pharmaceutical business for foreign markets

          Internationalization of biomedicine
          HEC is an advanced preparation international enterprise in China, possessing strong international R&D and clinical promotion capabilities, drug registration capabilities and intellectual property rights layout capabilities. At present, more than 30 varieties of generic drugs have been approved in the United States and Europe, and 4 new drugs and 1 biosimilar drug have been clinically launched overseas, and another biosimilar drug is planned to be clinically launched overseas. In 2022, HEC successfully invalidated the US patent of Novartis fingolimod, becoming the first Chinese company to successfully challenge the patent of an original drug in the US. Sunshine Lake Pharma has established sales branches in 15 countries including Singapore, Japan, the United States, and Germany. At present, the German company has a complete and mature operating system, and has the qualifications to sell medicines throughout Europe, which ranks 14th in the number of bids won by the insurance company AOK.
          HEC international product line of new drugs and biological drugs
          Drug classificationDrug nameTherapeutic fieldHighlights of the drug
          Small molecule new drug
          HEC68498Physical painTarget differentiation
          HEC96719Non-alcoholic fatty liver diseasePotential best-in-class, diverse potential indications
          Yinfenidone hydrochlorideIdiopathic pulmonary fibrosis IPFPotential best-in-class, broad market in China and the United States
          Biological new drugs and biosimilars
          Insulin glargineDiabetesQuality comparable to original research, planned to be listed in the United States
          Insulin aspartDiabetesQuality comparable to original research, planned to be listed in the United States
          GLP-1/FGF21 Dual-target biological drugType 2 diabetes, NASHExpected to become a global First-in-class

          Fermentation Raw Materials

          HEC's biochemical fermentation raw materials are mainly macrolide products (the raw materials of broad-spectrum antibiotics), the technology level and product quality are among the best in the world, and the output accounts for more than 65% of the global standard market.

          Core customer:

          圖片名稱
          圖片名稱
          圖片名稱
          圖片名稱
          圖片名稱
          圖片名稱
          圖片名稱

          HEC Medicine—Production System

          Shaoguan, Guangdong

          API factory

          圖片名稱
          圖片名稱

          Dongguan, Guangdong

          Oral solid dosage production base

          Yichang, Hubei

          Domestic preparation factory

          圖片名稱
          圖片名稱

          Yichang, Hubei

          API factory

          亚洲 日韩 欧美 春色-亚洲精品国产第一综合99久久-亚洲人精品亚洲人成在线-白丝无内液液酱夹腿自慰
        1. <pre id="bq1g9"><label id="bq1g9"></label></pre><pre id="bq1g9"></pre>
        2. <td id="bq1g9"></td>
            <acronym id="bq1g9"></acronym>

              <td id="bq1g9"><ruby id="bq1g9"></ruby></td>

              <track id="bq1g9"><strike id="bq1g9"></strike></track>

              <tr id="bq1g9"><s id="bq1g9"></s></tr>

              <td id="bq1g9"><option id="bq1g9"></option></td>
            1. <p id="bq1g9"><ruby id="bq1g9"><menu id="bq1g9"></menu></ruby></p>
                <track id="bq1g9"><ruby id="bq1g9"><tt id="bq1g9"></tt></ruby></track>